Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danay Saavedra

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Oncology|February 14, 2022
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based ChemotherapyGisela María Suárez, Mauricio Catalá, Yadira Peña, et al.
Frontiers in Public Health|August 8, 2022
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World ScenarioHenrry Diaz, Jorge Jiménez, Aray Hernández, et al.
Gerontology|October 26, 2020
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19Yayquier Díaz, Mayra Ramos-Suzarte, Yordanis Martín, et al.
Frontiers in Oncology|August 22, 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLCRachel Evans, Kelvin Lee, Paul K Wallace, et al.
Clinical & Translational Immunology|December 11, 2020
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumabArmando Caballero, Lázaro M Filgueira, Julio Betancourt, et al.
Vaccines|August 29, 2024
PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD PatientsJenysbel de la C Hernandez Reyes, Orestes Santos Morales, Laura Hernandez Moreno, et al.
Frontiers in Oncology|February 2, 2024
Safety and effectiveness of CIMAvax-EGF administered in community polyclinicsRamón A Ortiz Carrodeguas, Geidy Lorenzo Monteagudo, Pedro P Guerra Chaviano, et al.
Immunotherapy|March 21, 2022
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatmentHenrry Diaz Londres, Jorge Jiménez Armada, Aray Hernández Martínez, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Oncology|February 14, 2022
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based ChemotherapyGisela María Suárez, Mauricio Catalá, Yadira Peña, et al.
Frontiers in Public Health|August 8, 2022
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World ScenarioHenrry Diaz, Jorge Jiménez, Aray Hernández, et al.
Gerontology|October 26, 2020
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19Yayquier Díaz, Mayra Ramos-Suzarte, Yordanis Martín, et al.
Frontiers in Oncology|August 22, 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLCRachel Evans, Kelvin Lee, Paul K Wallace, et al.
Clinical & Translational Immunology|December 11, 2020
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumabArmando Caballero, Lázaro M Filgueira, Julio Betancourt, et al.
Vaccines|August 29, 2024
PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD PatientsJenysbel de la C Hernandez Reyes, Orestes Santos Morales, Laura Hernandez Moreno, et al.
Frontiers in Oncology|February 2, 2024
Safety and effectiveness of CIMAvax-EGF administered in community polyclinicsRamón A Ortiz Carrodeguas, Geidy Lorenzo Monteagudo, Pedro P Guerra Chaviano, et al.
Immunotherapy|March 21, 2022
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatmentHenrry Diaz Londres, Jorge Jiménez Armada, Aray Hernández Martínez, et al.
Pageof 3